CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
April 01, 2024 08:00 ET
|
CervoMed Inc.
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash...
CervoMed to Participate in Upcoming Investor Conferences
March 28, 2024 16:05 ET
|
CervoMed Inc.
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that...
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
March 28, 2024 08:30 ET
|
CervoMed Inc.
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million tied...
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
March 05, 2024 08:00 ET
|
CervoMed Inc.
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod effects on GFAP correlated to clinical outcomes assessed by...
CervoMed to Participate in the BIO CEO and Investor Conference
February 21, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
February 12, 2024 08:00 ET
|
CervoMed Inc.
-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b...
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
February 07, 2024 08:30 ET
|
CervoMed Inc.
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating...
CervoMed to Participate in the Emerging Growth Conference 67
February 05, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
CervoMed to Participate in the Emerging Growth Conference 66
January 05, 2024 08:00 ET
|
CervoMed Inc.
BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...